TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00135954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide and steroids
Description: comparison of difference in time of start of therapy

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide and steroids
Description: comparison of difference in time of start of therapy
Study: NCT04078282

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: see above

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention group
Description: see above
Study: NCT01144312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: an initial intravenous bolus of fentanyl 100 μg and infusion of fentanyl at variable rates ranging from 250 to 400 μg/hr
Study: NCT03221582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EBR/GZR
Description: Elbasvir and Grazoprevir (EBR/GZR) tablet by mouth, once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EBR/GZR
Description: Elbasvir and Grazoprevir (EBR/GZR) tablet by mouth, once daily.
Study: NCT01787526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ferric carboxymaltose
Description: 1 g intravenously per infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral iron
Description: oral tablets of 100mg iron over 8 weeks, total dose 10g
Study: NCT00475059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cimetidine arrow
Description: patients who received cimétidine
Study: NCT03074422

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: Hypnosis session performed by a board certified senior anesthesiologist during the frame fixation on the patient's head.
Study: NCT03713762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peribulbar block 1 lidocaine/bupivacaine
Description: Peribulbar block: 100 mg of lidocaine 5% and 15 mg of bupivacaine 0.5% for a total volume of the anesthetic mixture of 5 ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peribulbar block 2 lidocaine/bupivacaine/fentanyl
Description: Peribulbar block: 100 mg of lidocaine 5%, 15 mg of 0.5% bupivacaine and 50 mcg of fentanyl citrate for a total volume of the anesthetic mixture of 6 ml.
Study: NCT03524326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib Pill
Description: 24 mg oral daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib Pill
Description: 20 mg oral daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib Pill
Description: 14 mg oral daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 400mg/m2 IV, then 500mg/m2 IV weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib Pill
Description: 10 mg oral daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib Pill
Description: 4 mg oral daily
Study: NCT01202773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2127399
Description: Administered Subcutaneously (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2127399
Description: Administered Subcutaneously (SC)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LY2127399
Description: Administered Subcutaneously (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Q4W
Description: Administered SC
Study: NCT04243499

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IV ICT01
Description: humanized anti-Butyrophilin 3A (BTN3A) monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IV ICT01
Description: humanized anti-Butyrophilin 3A (BTN3A) monoclonal antibody
Study: NCT01354600

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise or Sedentary
Description: Daily cycling exercise at 50% maximal aerobic fitness for a total of \~120 minutes/day or no daily exercise (sedentary)

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise or Sedentary
Description: Daily cycling exercise at 50% maximal aerobic fitness for a total of \~120 minutes/day or no daily exercise (sedentary)
Study: NCT01915381

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: multimodal intervention
Description: All subjects received a multimodal intervention consist in a multimodal program with an educational approach, where therapist advice about benefits of PA during the exercises, to promote PA with brochure-based decalogue

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multimodal intervention
Description: All subjects received a multimodal intervention consist in a multimodal program with an educational approach, where therapist advice about benefits of PA during the exercises, to promote PA with brochure-based decalogue
Study: NCT01370434

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: PAD combination
Description: * Bortezomib 1.3 mg/m2/d iv on D 1, 4, 8, 11~* Doxorubicin 9 mg/m2/d iv on D 1-4~* Dexamethasone 40mg/d po or iv on D1-4, 8-11
Study: NCT03082820

Intervention type: DIAGNOSTIC_TEST
Intervention: Pain-related evoked potentials (PREP)
Description: PREP were performed bilaterally with a concentric surface electrode at twice the individual pain threshold.

Intervention type: DIAGNOSTIC_TEST
Intervention: Pain-related evoked potentials (PREP)
Description: PREP were performed bilaterally with a concentric surface electrode at twice the individual pain threshold.

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative Sensory Testing (QST)
Description: QST was performed bilaterally following the protocol of the German Network on Neuropathic Pain.

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative Sensory Testing (QST)
Description: QST was performed bilaterally following the protocol of the German Network on Neuropathic Pain.

Intervention type: DIAGNOSTIC_TEST
Intervention: Nerve conduction studies (NCS)
Description: NCS were performed with patients only.
Study: NCT00263796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 10 international units = 1 cc, IV over 4 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline, IV over 4 hours
Study: NCT00279799

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Afiya HIV Prevention Intervention
Description: Group-based session plus individually tailored HIV prevention phone sessions
Study: NCT01202773

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Q2W
Description: Administered SC
Study: NCT00279799

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Afiya HIV prevention intervention
Description: Afiya group-based intervention + nutrition phone sessions (attention control)
Study: NCT01711671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKN-01 300 mg
Description: 300 mg IV infusion of DKN-01 administered twice per 28 day cycle on Days 1 and 15, plus lenalidomide/dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKN-01 600 mg
Description: 600 mg IV infusion of DKN-01 administered twice per 28 day cycle on Days 1 and 15, plus lenalidomide/dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Current approved standard of care
Study: NCT00924183

Intervention type: OTHER
Intervention: Treatment-as-usual
Study: NCT01067859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinaciguat (BAY58-2667)
Description: Infusion of 25 µg/h during 48 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinaciguat (BAY58-2667)
Description: Infusion of 10 µg/h during 48 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Infusion of placebo during 48 hours
Study: NCT03438305

Intervention type: OTHER
Intervention: sonar assessment of gastric volume in Diabetic patients
Description: assessment of gastric volume in Diabetic Patients
Study: NCT05809960

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine nursing care
Description: Routine nursing care was given to the control group. The clinical routine has not been exceeded. It includes discharge training for the surgery.
Study: NCT01557504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin/metformin XR
Description: Fixed dose combination tablet of immediate-release sitagliptin 50 mg and extended-release (XR) metformin 1000 mg (total daily dose, sitagliptin 100 mg and metformin XR 2000 mg).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to fixed dose combination tablet of sitagliptin and metformin. Matching placebo tablets are same size, shape and color as the active product, but do not contain any markings.
Study: NCT03438305

Intervention type: OTHER
Intervention: sonar assessment of gastric volume in Non Diabetic patients
Description: assessment of gastric volume in Non- Diabetic Patients
Study: NCT04517981

Intervention type: BEHAVIORAL
Intervention: Psychological intervention
Description: Choose according to the wishes of the enrolled subjects and the results of the evaluation

Intervention type: BEHAVIORAL
Intervention: Psychological intervention
Description: Choose according to the wishes of the enrolled subjects and the results of the evaluation

Intervention type: OTHER
Intervention: Comprehensive intervention
Description: Choose according to the wishes of the enrolled subjects and the results of the evaluation
Study: NCT01557504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to fixed dose combination tablet of sitagliptin and metformin. Matching placebo tablets are same size, shape and color as the active product, but do not contain any markings.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Concomitant use of metformin is permitted during the study provided the participant has been receiving a stable metformin dose for at least 12 weeks prior to the dose of study drug. Administration of metformin will be withheld for 24 hours prior to study drug administration and for 24 hours postdose.
Study: NCT03823677

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypoxia
Description: hypoxia

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypoxia
Description: hypoxia

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypoxia
Description: hypoxia
Study: NCT01557504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Concomitant use of metformin is permitted during the study provided the participant has been receiving a stable metformin dose for at least 12 weeks prior to the dose of study drug. Administration of metformin will be withheld for 24 hours prior to study drug administration and for 24 hours postdose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Thyroid hormone
Description: Concomitant use of thyroid hormone (eg, levothyroxine) is permitted during the study provided the participant has been receiving a stable dose for at least 12 weeks prior to study drug administration and is euthyroid as documented by thyroid stimulating hormone testing at prestudy. Administration of thyroid hormone will be withheld for 24 hours prior to study drug administration and for 24 hours postdose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thyroid hormone
Description: Concomitant use of thyroid hormone (eg, levothyroxine) is permitted during the study provided the participant has been receiving a stable dose for at least 12 weeks prior to study drug administration and is euthyroid as documented by thyroid stimulating hormone testing at prestudy. Administration of thyroid hormone will be withheld for 24 hours prior to study drug administration and for 24 hours postdose.
Study: NCT00869102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1
Description: intravenous, 124,5 pmol/kg body weight
Study: NCT03170362

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic Test
Description: The intervention is a battery of pharmacogenetic test results that mostly affect the metabolism of antidepressants and other medications.
Study: NCT00299325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimonabant
Description: Tablet, oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Rimonabant)
Description: Tablet, oral administration
Study: NCT03823677

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypoxia
Description: hypoxia

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypoxia
Description: hypoxia

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypoxia
Description: hypoxia

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypoxia
Description: hypoxia

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypoxia
Description: hypoxia

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypoxia
Description: hypoxia

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypoxia
Description: hypoxia

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypoxia
Description: hypoxia

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypoxia
Description: hypoxia
Study: NCT01337609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganeden BC30
Description: 2 billion CFU per capsule; One pill daily for 60 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (sugar pill)
Description: 1 pill daily for 60 days
Study: NCT00299325

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mild hypocaloric diet
Description: Calculated by the dietitian based on the estimated basal metabolism rate and the physical activity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mild hypocaloric diet
Description: Calculated by the dietitian based on the estimated basal metabolism rate and the physical activity
Study: NCT04171700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Oral rucaparib will be administered twice daily. The starting dose will be 600 mg daily (BID).
Study: NCT01462994

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Blood will be withdrawn at baseline and in intervals of 3 months for a total period of 2 years
Study: NCT01134900

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacy Dashboard Review and Intervention
Description: Clinical pharmacist reviews patients on dashboard and makes intervention with providing team when necessary.
Study: NCT04320069

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Omnipod Horizon™ Automated Glucose Control System
Description: Omnipod Horizon™ Automated Glucose Control System use in Manual Mode
Study: NCT04081207

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AAC for Language Recovery (AAC-LaRc)
Description: iPads will be programmed with a personalized communication application (app) and a structured 4-step intervention will be employed to instruct patients how to cue themselves during anomic events via pictures, text, or speak buttons.
Study: NCT03913273

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AMI transtibial amputation
Description: Two Agonist-antagonist myoneural interfaces (AMIs) were surgically constructed during a modified transtibial amputation procedure. Each AMI was made of natively innervated and vascularized muscle segments - an agonist and antagonist - that were surgically connected in series within the amputated residuum. Tarsal tunnels, including segments of each tunnel's native tendon component, were procured from the amputated joint. The tunnels were affixed to the residual limb tibia and the AMIs were constructed by coaptation of an agonist and an antagonist muscle to either end of the tendon passing through the tunnel. Consequently, the force produced by one muscle stretches its partner such that the AMI can communicate signals from the mechanoreceptors in both muscles to the central nervous system.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard transtibial amputation
Description: A standard transtibial amputation was performed according to traditional techniques. No surgical construction of agonist-antagonist myoneural interfaces (AMIs) was performed.
Study: NCT03791125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salvianolic Acid A
Description: 4 anticipated doses are 30 mg, 90 mg, 180 mg and 270 mg, respectively. All of these are single-dose study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo tablets containing no salvianolic acid A will be given to healthy subjects.
Study: NCT02811029

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: measurement of phonology
Description: measurement of phonology will be assess using BILO-3, EDA, VS and VL tests
Study: NCT03140748

Intervention type: OTHER
Group type: OTHER
Intervention: To evaluate the initial levels and kinetics of serum β-D-glucan
Description: To evaluate the initial levels and kinetics of serum β-D-glucan during fungal peritonitis compared to a control group of yeast-free peritonitis

Intervention type: OTHER
Group type: OTHER
Intervention: To evaluate the initial levels and kinetics of serum β-D-glucan
Description: To evaluate the initial levels and kinetics of serum β-D-glucan during fungal peritonitis compared to a control group of yeast-free peritonitis
Study: NCT02084953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-791325

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching BMS-791325
Study: NCT01865591

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound-based Renal Denervation
Study: NCT04898608

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intradialytic Exercise
Description: Participants will do concurrent exercise (a combination of aerobic exercise and resistance training) for 30-60 minutes during the second hour of their routine hemodialysis sessions.~To determine the intensity of the prescribed exercise, maximum heart rate is used for aerobic workout and 1RM for resistance protocols.~Exercises will be performed at a moderate exercise intensity (12-14 on the Borg RPE Scale).~All protocols are tailor-made based on each individual's needs and physical abilities.
Study: NCT03939286

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical-neurological and neuropsychological tests
Description: The tests include established standardized questionnaires and detailed clinical neuropsychological examinations (e.g., tests on cognition and perception). In order to avoid exercise effects in multiple examinations, so-called parallel procedures should be used.

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical-neurological and neuropsychological tests
Description: The tests include established standardized questionnaires and detailed clinical neuropsychological examinations (e.g., tests on cognition and perception). In order to avoid exercise effects in multiple examinations, so-called parallel procedures should be used.
Study: NCT01337609

Intervention type: OTHER
Group type: OTHER
Intervention: Ganeden BC30, Placebo (sugar pill)
Description: Ganeden BC30 (2 billion CFU per capsule), One capsule daily for 30 days Sugar Pill (placebo), One capsule daily for 30 days
Study: NCT03939286

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood sampling
Description: Venous blood sampling (40 ml) is performed according to the usual criteria of sterile working at baseline and after intervention.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood sampling
Description: Venous blood sampling (40 ml) is performed according to the usual criteria of sterile working at baseline and after intervention.

Intervention type: OTHER
Group type: OTHER
Intervention: Assessment of physical activity via fitness tracker/diary
Description: All study participants, regardless of group classification, are randomly selected for a period of one week using Fitbit Charge 2® fitness trackers. The study participants are asked in this context to pursue their regular activity and to wear the bracelets for a week throughout. All study participants are asked to document their activities in a hand-written diary.

Intervention type: OTHER
Group type: OTHER
Intervention: Assessment of physical activity via fitness tracker/diary
Description: All study participants, regardless of group classification, are randomly selected for a period of one week using Fitbit Charge 2® fitness trackers. The study participants are asked in this context to pursue their regular activity and to wear the bracelets for a week throughout. All study participants are asked to document their activities in a hand-written diary.

Intervention type: OTHER
Group type: OTHER
Intervention: MRI-examinations
Description: Standard MRI-methods, Sodium MRI, Phosphor MRS, Wholebody-Fat-MRI

Intervention type: OTHER
Group type: OTHER
Intervention: MRI-examinations
Description: Standard MRI-methods, Sodium MRI, Phosphor MRS, Wholebody-Fat-MRI
Study: NCT04071938

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Teaching to GPs
Description: Educational modules on bladder, bowel and skin-care, and pain management will be provided to participating GPs by Spinal Cord Injury specialists

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Site visits to GP practices
Description: Visits by specialized nurses to the participating GPs at their practices to support the establishment of specialized care on-site
Study: NCT00599326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Description: 250 mg of deferasirox once daily for 6 months
Study: NCT01101737

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse-led blood pressure clinic
Description: Blood pressure will be measured according to protocol.For patients with blood pressure above optimal targets, treatment changes will be discussed with the patient, a visiting consultant physician and the patient's GP. If they agree, the GP will intensify anti-hypertensive treatment with monthly follow up by the specialist nurse until BP targets are achieved.